These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 30917791)

  • 1. Impact of primary colorectal Cancer location on the KRAS status and its prognostic value.
    Xie MZ; Li JL; Cai ZM; Li KZ; Hu BL
    BMC Gastroenterol; 2019 Mar; 19(1):46. PubMed ID: 30917791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location.
    Sasaki K; Margonis GA; Wilson A; Kim Y; Buettner S; Andreatos N; Gani F; Amini N; Spolverato G; Pawlik TM
    Ann Surg Oncol; 2016 Oct; 23(11):3736-3743. PubMed ID: 27352204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS mutation status between left- and right-sided colorectal cancer: are there any differences in computed tomography?
    Yu MM; Shi D; Li Q; Li JB; Li Q; Yu RS
    Jpn J Radiol; 2023 Jan; 41(1):83-91. PubMed ID: 35976561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The interplay of KRAS mutational status with tumor laterality in non-metastatic colorectal cancer: An international, multi-institutional study in patients with known KRAS, BRAF, and MSI status.
    Kamphues C; Kadowaki S; Amini N; van den Berg I; Wang J; Andreatos N; Sakamoto Y; Ogura T; Kakuta M; Pikouli A; Geka D; Daitoku N; Theochari M; Buettner S; Akiyama T; Antoniou E; Pikoulis E; Theodoropoulos G; Imai K; Ijzermans JNM; Margonis GA; Akagi K; Kreis ME
    J Surg Oncol; 2021 Mar; 123(4):1005-1014. PubMed ID: 33368279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of
    Olmedillas-López S; Lévano-Linares DC; Alexandre CLA; Vega-Clemente L; Sánchez EL; Villagrasa A; Ruíz-Tovar J; García-Arranz M; García-Olmo D
    World J Gastroenterol; 2017 Oct; 23(39):7087-7097. PubMed ID: 29093617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of primary tumor sidedness on survival in early-onset colorectal cancer by stage: A National Veterans Affairs retrospective analysis.
    Azar I; Al Masalmeh N; Esfandiarifard S; Virk G; Kiwan W; Frank Shields A; Mehdi S; Philip PA
    Cancer Med; 2021 May; 10(9):2987-2995. PubMed ID: 33797856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy.
    Maus MK; Hanna DL; Stephens CL; Astrow SH; Yang D; Grimminger PP; Loupakis F; Hsiang JH; Zeger G; Wakatsuki T; Barzi A; Lenz HJ
    Pharmacogenomics J; 2015 Aug; 15(4):354-62. PubMed ID: 25532759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic Profile of Colorectal Cancer: Interplay Between Primary Tumor Location and KRAS Status.
    Zihui Yong Z; Ching GTH; Ching MTC
    J Surg Res; 2020 Feb; 246():325-334. PubMed ID: 30737098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating
    Ntavatzikos A; Spathis A; Patapis P; Machairas N; Peros G; Konstantoudakis S; Leventakou D; Panayiotides IG; Karakitsos P; Koumarianou A
    World J Gastroenterol; 2017 Aug; 23(32):5913-5924. PubMed ID: 28932083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
    Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
    BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative splicing expands the prognostic impact of KRAS in microsatellite stable primary colorectal cancer.
    Eilertsen IA; Sveen A; Strømme JM; Skotheim RI; Nesbakken A; Lothe RA
    Int J Cancer; 2019 Feb; 144(4):841-847. PubMed ID: 30121958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer.
    Reggiani Bonetti L; Barresi V; Maiorana A; Manfredini S; Caprera C; Bettelli S
    Dis Markers; 2018; 2018():2959801. PubMed ID: 30018674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study.
    Chen KH; Shao YY; Chen HM; Lin YL; Lin ZZ; Lai MS; Cheng AL; Yeh KH
    BMC Cancer; 2016 May; 16():327. PubMed ID: 27221731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical baseline and prognostic difference of platelet lymphocyte ratio (PLR) in right-sided and let-sided colon cancers.
    Yang L; He W; Kong P; Jiang C; Yang Q; Xie Q; Xia LP
    BMC Cancer; 2017 Dec; 17(1):873. PubMed ID: 29262803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
    Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
    Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association of clinicopathological features and survival in colorectal cancer patients with kras mutation status.
    Akman T; Oztop I; Baskin Y; Unek IT; Demir N; Ellidokuz H; Yilmaz AU
    J Cancer Res Ther; 2016; 12(1):96-102. PubMed ID: 27072218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological and molecular differences between right-sided and left-sided colorectal cancer in Japanese patients.
    Natsume S; Yamaguchi T; Takao M; Iijima T; Wakaume R; Takahashi K; Matsumoto H; Nakano D; Horiguchi SI; Koizumi K; Miyaki M
    Jpn J Clin Oncol; 2018 Jul; 48(7):609-618. PubMed ID: 29767751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
    Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
    J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern.
    Prasanna T; Karapetis CS; Roder D; Tie J; Padbury R; Price T; Wong R; Shapiro J; Nott L; Lee M; Chua YJ; Craft P; Piantadosi C; Sorich M; Gibbs P; Yip D
    Acta Oncol; 2018 Nov; 57(11):1438-1444. PubMed ID: 30035653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.
    Zlobec I; Bihl MP; Schwarb H; Terracciano L; Lugli A
    Int J Cancer; 2010 Jul; 127(2):367-80. PubMed ID: 19908233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.